.Charles Baum, M.D., Ph.D., who oversaw Mirati Therapies’ $ 5.8 billion sale to Bristol Myers Squibb in 2013, is actually taking the controls of young biotech Terremoto Biosciences.Baum’s “significant adventure in medicine advancement, and proven record beforehand high-impact medications, will contribute,” outgoing CEO Peter Thompson, M.D., stated in a July 25 launch. Thompson will definitely retain his chair as board chairperson..Baum, a qualified physician-scientist, was the founder, head of state and also chief executive officer of oncology-focused Mirati. Just before that, he assisted create cancer drugs at Pfizer and Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Currently, Baum will certainly serve as CEO at Terremoto, a company establishing tiny particles to target disease-causing proteins– like those discovered in malignant growth tissues– using covalent connects. Existing treatments that utilize covalent bonds primarily target the amino acid cysteine. However, of the twenty amino acids that compose proteins, cysteine is actually the minimum common.
Terremoto is actually rather targeting one of the important amino acids, lysine, which is discovered in mostly all proteins.Through targeting amino acid lysine and also other amino acids, Terremoto expects to alleviate previously undruggable health conditions as well as produce first-in-class medicines..The biotech, located in South San Francisco, brought up $75 thousand in set A backing in 2022. A little bit of much more than a year eventually, the biotech more than doubled that amount in a $175 million series B.